| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.53 | 0.1 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |